Brokers Issue Forecasts for Zoetis’ Q2 Earnings (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – Research analysts at Zacks Research decreased their Q2 2025 earnings per share estimates for Zoetis in a research report issued on Monday, November 25th. Zacks Research analyst E. Bagri now anticipates that the company will earn $1.66 per share for the quarter, down from their prior estimate of $1.68. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. Zacks Research also issued estimates for Zoetis’ Q3 2025 earnings at $1.65 EPS, FY2025 earnings at $6.37 EPS, Q2 2026 earnings at $1.76 EPS and FY2026 earnings at $6.91 EPS.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.36 EPS.

Other analysts have also recently issued research reports about the stock. Stifel Nicolaus raised their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. BTIG Research raised their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Piper Sandler raised their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. JPMorgan Chase & Co. raised their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Trading Up 0.6 %

NYSE:ZTS opened at $176.74 on Thursday. The stock’s 50 day simple moving average is $184.51 and its 200-day simple moving average is $180.81. Zoetis has a 12-month low of $144.80 and a 12-month high of $201.92. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The firm has a market cap of $79.74 billion, a P/E ratio of 33.22, a PEG ratio of 2.70 and a beta of 0.90.

Institutional Trading of Zoetis

Large investors have recently modified their holdings of the business. Darwin Wealth Management LLC purchased a new stake in Zoetis in the 3rd quarter valued at approximately $31,000. First Personal Financial Services purchased a new position in Zoetis during the third quarter worth $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis in the third quarter worth $33,000. Dunhill Financial LLC lifted its position in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares in the last quarter. Finally, Quarry LP boosted its stake in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after acquiring an additional 153 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a $0.432 dividend. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.